Markt für die Behandlung leichter kognitiver Beeinträchtigungen (MCI) im asiatisch-pazifischen Raum, nach Krankheitstyp (amnestische MCI, nicht-amnestische MCI), Behandlungstyp (Medikamente, Therapie), Verabreichungsweg (oral, parenteral, andere), Arzneimitteltyp (Markenpräparate, Generika), Geschlecht (männlich, weiblich), Alterstyp (Kind, Erwachsener, Geriatrie), Endverbraucher (Krankenhäuser, Fachkliniken, häusliche Pflege, andere), Vertriebskanal (Krankenhausapotheken, Einzelhandelsapotheke), Land (China, Japan, Indien, Südkorea, Australien, Singapur, Thailand, Malaysia, Indonesien, Vietnam, Philippinen, übriger asiatisch-pazifischer Raum) – Branchentrends und Prognose bis 2029
Marktanalyse und Einblicke : Markt für die Behandlung leichter kognitiver Beeinträchtigungen (MCI) im asiatisch-pazifischen Raum
Der Markt für die Behandlung leichter kognitiver Beeinträchtigungen (MCI) dürfte im Prognosezeitraum 2022 bis 2029 an Marktwachstum gewinnen. Data Bridge Market Research analysiert, dass der Markt im Prognosezeitraum 2022 bis 2029 mit einer durchschnittlichen jährlichen Wachstumsrate (CAGR) von 10,1 % wächst und bis 2029 voraussichtlich 24.974,93 Tausend USD erreichen wird. Das breite Portfolio der großen Akteure und das wachsende Bewusstsein für leichte kognitive Beeinträchtigungen dürften das Marktwachstum vorantreiben.
Leichte kognitive Beeinträchtigung (MCI) ist ein frühes Stadium des Gedächtnisverlusts oder des Verlusts anderer kognitiver Fähigkeiten (wie Sprache oder visuelle/räumliche Wahrnehmung) bei Personen, die die Fähigkeit behalten, die meisten Aktivitäten des täglichen Lebens selbstständig auszuführen. MCI kann aus verschiedenen Gründen auftreten, und Personen mit MCI können Demenz entwickeln. MCI kann ein frühes Stadium des Krankheitskontinuums neurodegenerativer Erkrankungen, einschließlich Alzheimer, sein. Bei einigen Personen normalisiert sich die kognitive Beeinträchtigung aufgrund von MCI oder bleibt stabil.
Leichte kognitive Beeinträchtigungen (MCI) sind durch Beeinträchtigungen in einem einzigen kognitiven Bereich, normalerweise dem Gedächtnis (amnestische MCI), oder durch mäßige Beeinträchtigungen in mehreren kognitiven Bereichen gekennzeichnet. Die Prävalenz von MCI unter Personen, die in Langzeitpflegeeinrichtungen leben, variiert zwischen 5 % und 10 % in vielen Pflegeheimen bis zu 30 %. Die am häufigsten auftretende Form von MCI ist der amnestische Typ. Weniger häufige Varianten von MCI weisen lokalisierte Beeinträchtigungen anderer kognitiver Bereiche auf, wie z. B. exekutive Dysfunktion bei Frontotemporaler Lobärdegeneration (FTLD).
Wichtige Faktoren, die das Wachstum des globalen Marktes für die Behandlung leichter kognitiver Beeinträchtigungen (MCI) vorantreiben, sind die Zunahme der Zahl älterer Patienten. Die laufende Forschung zur Suche nach der perfekten und wirksamen Heilung dürfte das Marktwachstum in der kommenden Zeit vorantreiben. Die hohen Kosten der Therapieverfahren und die mit dem Produkt verbundenen Nebenwirkungen können das Marktwachstum jedoch hemmen.
Der Marktbericht zur Behandlung leichter kognitiver Beeinträchtigungen (MCI) enthält Einzelheiten zu Marktanteilen, neuen Entwicklungen und Produktpipeline-Analysen, Auswirkungen inländischer und lokaler Marktteilnehmer, analysiert Chancen in Bezug auf neu entstehende Umsatzbereiche, Änderungen der Marktvorschriften, Produktzulassungen, strategische Entscheidungen, Produkteinführungen, geografische Expansionen und technologische Innovationen auf dem Markt. Um die Analyse und das Marktszenario zur Behandlung leichter kognitiver Beeinträchtigungen (MCI) zu verstehen, wenden Sie sich an Data Bridge Market Research, um ein Analyst Briefing zu erhalten. Unser Team hilft Ihnen dabei, eine umsatzwirksame Lösung zu entwickeln, mit der Sie Ihr gewünschtes Ziel erreichen.
Behandlung leichter kognitiver Beeinträchtigungen (MCI) – Marktumfang und Marktgröße
Der Markt für die Behandlung leichter kognitiver Beeinträchtigungen (MCI) ist segmentiert nach Krankheitstyp, Behandlungsart, Verabreichungsweg, Arzneimitteltyp, Geschlecht, Alter, Vertriebskanal und Endverbraucher. Das Wachstum zwischen den Segmenten hilft Ihnen bei der Analyse von Nischenwachstumsbereichen und Strategien zur Marktbearbeitung und zur Bestimmung Ihrer wichtigsten Anwendungsbereiche und der Unterschiede in Ihren Zielmärkten.
- Basierend auf dem Krankheitstyp ist der Markt für die Behandlung leichter kognitiver Beeinträchtigungen (MCI) in amnestische MCI und nicht-amnestische MCI segmentiert. Im Jahr 2022 wird das Segment amnestischer MCI voraussichtlich den globalen Markt für die Behandlung leichter kognitiver Beeinträchtigungen (MCI) dominieren, was auf die Zunahme der älteren Bevölkerung weltweit zurückzuführen ist.
- Basierend auf der Behandlungsart ist der Markt für die Behandlung leichter kognitiver Beeinträchtigungen (MCI) in Medikamente und Therapie unterteilt. Im Jahr 2022 wird das Medikamentensegment voraussichtlich den globalen Markt für die Behandlung leichter kognitiver Beeinträchtigungen (MCI) dominieren, da es unmittelbare und effektive Auswirkungen auf die MCI-Symptome hat.
- Basierend auf der Verabreichungsmethode ist der Markt für die Behandlung leichter kognitiver Beeinträchtigungen (MCI) in orale und parenterale Verabreichung und andere unterteilt. Im Jahr 2022 wird das orale Segment voraussichtlich den globalen Markt für die Behandlung leichter kognitiver Beeinträchtigungen (MCI) dominieren, da es nicht invasiv ist, eine hohe Patientencompliance aufweist, bequem zu handhaben ist und keine spezifischen sterilen Bedingungen erfordert.
- Basierend auf dem Medikamententyp ist der Markt für die Behandlung leichter kognitiver Beeinträchtigungen (MCI) in Marken- und Generikaprodukte unterteilt. Im Jahr 2022 wird das Generikasegment voraussichtlich den globalen Markt für die Behandlung leichter kognitiver Beeinträchtigungen (MCI) dominieren, da es im Vergleich zu Markenmedikamenten kostengünstiger ist.
- Basierend auf dem Geschlecht ist der Markt für die Behandlung leichter kognitiver Beeinträchtigungen (MCI) in männlich und weiblich unterteilt. Im Jahr 2022 wird das männliche Segment voraussichtlich den globalen Markt für die Behandlung leichter kognitiver Beeinträchtigungen (MCI) dominieren, da bei der männlichen Bevölkerung ein Anstieg der psychischen Komplikationen zu beobachten ist.
- Basierend auf dem Alter ist der Markt für die Behandlung leichter kognitiver Beeinträchtigungen (MCI) in Kinder, Erwachsene und Geriatrie segmentiert. Im Jahr 2022 wird das geriatrische Segment voraussichtlich den globalen Markt für die Behandlung leichter kognitiver Beeinträchtigungen (MCI) dominieren, da die Zahl der gefährdeten älteren Menschen stark zunimmt, wobei die höchste Wachstumsrate in der asiatischen Region zu verzeichnen ist.
- Basierend auf den Endverbrauchern ist der Markt für die Behandlung leichter kognitiver Beeinträchtigungen (MCI) in Krankenhäuser, Fachkliniken, häusliche Pflege und andere unterteilt. Im Jahr 2022 wird das Krankenhaussegment voraussichtlich den globalen Markt für die Behandlung leichter kognitiver Beeinträchtigungen (MCI) dominieren, da das Bewusstsein für eine bessere und wirksamere Behandlung während Krankenhausaufenthalten gestiegen ist.
- Basierend auf dem Vertriebskanal ist der Markt für die Behandlung leichter kognitiver Beeinträchtigungen (MCI) in Krankenhausapotheken und Einzelhandelsapotheken unterteilt. Im Jahr 2022 wird das Segment der Krankenhausapotheken voraussichtlich den globalen Markt für die Behandlung leichter kognitiver Beeinträchtigungen (MCI) dominieren, da die Interaktion mit zertifizierten Verschreibern und medizinischem Fachpersonal zur Verwendung von Antipsychotika und zur garantierten Bezahlung zunimmt.
Behandlung leichter kognitiver Beeinträchtigungen (MCI) Markt – Länderebeneanalyse
Der Markt für die Behandlung leichter kognitiver Beeinträchtigungen (MCI) wird analysiert und Informationen zur Marktgröße werden nach Land, Krankheitstyp, Behandlungstyp, Verabreichungsweg, Arzneimitteltyp, Geschlecht, Alter, Vertriebskanal und Endbenutzern wie oben angegeben bereitgestellt.
Die im Marktbericht zur Behandlung leichter kognitiver Beeinträchtigungen (MCI) abgedeckten Länder sind China, Südkorea, Japan, Indien, Australien, Singapur, Vietnam, Malaysia, Indonesien, Thailand, die Philippinen und der Rest der asiatisch-pazifischen Region.
Aufgrund der wachsenden geriatrischen Bevölkerung im Land wird China voraussichtlich den Markt für die Behandlung leichter kognitiver Beeinträchtigungen (MCI) im asiatisch-pazifischen Raum dominieren.
Der Länderabschnitt des Berichts enthält auch Angaben zu einzelnen marktbeeinflussenden Faktoren und Änderungen der Regulierung auf dem Inlandsmarkt, die sich auf die aktuellen und zukünftigen Markttrends auswirken. Datenpunkte wie Neuverkäufe, Ersatzverkäufe, demografische Daten des Landes, Regulierungsgesetze und Import-/Exportzölle sind einige der wichtigsten Anhaltspunkte, die zur Prognose des Marktszenarios für einzelne Länder verwendet werden. Bei der Prognoseanalyse der Länderdaten werden auch die Präsenz und Verfügbarkeit globaler Marken und ihre Herausforderungen aufgrund großer oder geringer Konkurrenz durch lokale und inländische Marken sowie die Auswirkungen der Vertriebskanäle berücksichtigt.
Zunehmende strategische Aktivitäten wichtiger Marktteilnehmer zur Steigerung des Bewusstseins für die Behandlung leichter kognitiver Beeinträchtigungen (MCI) kurbeln das Marktwachstum dieses Marktes an.
Der Markt für die Behandlung leichter kognitiver Beeinträchtigungen (MCI) bietet Ihnen außerdem eine detaillierte Marktanalyse für jedes Land, das in einem bestimmten Markt wächst. Darüber hinaus bietet er detaillierte Informationen zur Strategie der Marktteilnehmer und ihrer geografischen Präsenz. Die Daten sind für den historischen Zeitraum von 2011 bis 2020 verfügbar.
Wettbewerbsumfeld und Behandlung leichter kognitiver Beeinträchtigungen (MCI) Marktanteilsanalyse
Die Wettbewerbslandschaft auf dem Markt für die Behandlung leichter kognitiver Beeinträchtigungen (MCI) bietet Details nach Wettbewerbern. Zu den Details gehören Unternehmensübersicht, Unternehmensfinanzen, erzielter Umsatz, Marktpotenzial, Investitionen in Forschung und Entwicklung, neue Marktinitiativen, Produktionsstandorte und -anlagen, Stärken und Schwächen des Unternehmens, Produkteinführung, Produkttestpipelines, Produktzulassungen, Patente, Produktbreite und -umfang, Anwendungsdominanz, Technologie-Lebenslinienkurve. Die oben angegebenen Datenpunkte beziehen sich nur auf den Fokus des Unternehmens in Bezug auf den Markt für die Behandlung leichter kognitiver Beeinträchtigungen (MCI).
Zu den wichtigsten Akteuren auf dem Markt für die Behandlung leichter kognitiver Beeinträchtigungen (MCI) zählen unter anderem Pfizer Inc., F. Hoffman La Roche Ltd, Novartis AG, Accord UK Ltd, Dr. Reddy's Laboratories Ltd, Hikma Pharmaceuticals PLC, Viatris Inc., Eisai. Co. Ltd., Sun Pharmaceuticals Ltd., Johnson & Johnson Services, Inc., Teva Pharmaceutical Industries Ltd., Mallinckrodt, AstraZeneca, Cipla Inc., Takeda Pharmaceutical Company Limited, Allergan Aesthetics, Lupin, Jubilant Pharmova Limited, Lannett, Aurobindo Pharma, UCB SA, Belgium und WOCKHARDT.
Zum Beispiel,
- Im Juli 2021 genehmigte die FDA Biogen Aduhelm (Aducanumab) zur Behandlung von Patienten mit Alzheimer-Krankheit im Rahmen des beschleunigten Zulassungsverfahrens
Zusammenarbeit, Produkteinführung, Geschäftsausweitung, Auszeichnungen und Anerkennungen, Joint Ventures und andere Strategien der Marktteilnehmer stärken die Präsenz des Unternehmens auf dem Markt für die Behandlung leichter kognitiver Beeinträchtigungen (MCI), was sich auch positiv auf das Gewinnwachstum des Unternehmens auswirkt.
SKU-
Erhalten Sie Online-Zugriff auf den Bericht zur weltweit ersten Market Intelligence Cloud
- Interaktives Datenanalyse-Dashboard
- Unternehmensanalyse-Dashboard für Chancen mit hohem Wachstumspotenzial
- Zugriff für Research-Analysten für Anpassungen und Abfragen
- Konkurrenzanalyse mit interaktivem Dashboard
- Aktuelle Nachrichten, Updates und Trendanalyse
- Nutzen Sie die Leistungsfähigkeit der Benchmark-Analyse für eine umfassende Konkurrenzverfolgung
Inhaltsverzeichnis
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET END USERS COVERAGE GRID
2.8 DISEASES TYPE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTLE
4.2 PORTERS
5 EPIDEMIOLOGY
6 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: REGULATORY SCENARIO
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASE IN VULNERABLE GERIATRIC POPULATION
7.1.2 INCREASE IN AIR POLLUTION IMPACTS COGNITIVE PERFORMANCE
7.1.3 INCREASING NATIONAL AND INTERNATIONAL INVESTMENTS IN RESEARCH AND DEVELOPMENT OF COGNITIVE DISORDERS TREATMENT
7.1.4 RISE IN INCIDENCE OF NON-COMMUNICABLE DISEASES DUE TO PHYSICAL INACTIVITY
7.2 RESTRAINTS
7.2.1 UNAVAILABILITY OF ANY SPECIFIC TREATMENT
7.2.2 SERIOUS ADVERSE RISK ASSOCIATED WITH MCI TREATMENT DRUGS
7.2.3 HIGH COST OF TREATMENT AND CARE MANAGEMENT IN MCI PATIENTS
7.3 OPPORTUNITIES
7.3.1 PROMOTING PATIENT MENTAL HEALTH PROGRAMS
7.3.2 INNOVATION IN ALTERNATIVE MILD COGNITIVE IMPAIRMENT TREATMENT
7.4 CHALLENGES
7.4.1 LONG PROCESS OF APPROVAL BY REGULATORY BODIES
7.4.2 LACK OF SKILLED PROFESSIONALS
8 COVID-19 IMPACT ON MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET
8.1 PRICE IMPACT
8.2 IMPACT ON DEMAND
8.3 IMPACT ON SUPPLY
8.4 STRATEGIC DECISIONS BY MANUFACTURERS
8.5 CONCLUSION
9 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISEASE TYPE
9.1 OVERVIEW
9.2 AMNESTIC MCI
9.3 NON-AMNESTIC MCI
10 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT
10.1 OVERVIEW
10.2 MEDICATION
10.2.1 CHOLINESTERASE INHIBITORS
10.2.1.1 DONEPEZIL
10.2.1.2 RIVASTIGMINE
10.2.1.3 OTHERS
10.2.2 BENZODIAZEPINES
10.2.2.1 DIAZEPAM
10.2.2.2 CLONAZEPAM
10.2.2.3 LORAZEPAM
10.2.2.4 TEMAZEPAM
10.2.2.5 ALPRAZOLAM
10.2.2.6 FLUNITRAZEPAM
10.2.2.7 FLURAZEPAM
10.2.2.8 ZOPICLONE
10.2.2.9 OTHERS
10.2.3 GLUTAMATE INHIBITORS
10.2.3.1 RILUZOLE
10.2.3.2 OTHERS
10.2.4 ANTIHISTAMINES
10.2.4.1 CETIRIZINE
10.2.4.2 BROMPHENIRAMINE
10.2.4.3 CHLORPHENIRAMINE
10.2.4.4 CLEMASTINE
10.2.4.5 DIPHENHYDRAMINE
10.2.4.6 FEXOFENADINE
10.2.4.7 LORATADINE
10.2.4.8 OTHERS
10.2.5 MAO INHIBITORS
10.2.5.1 ISOCARBOXAZID
10.2.5.2 PHENELZINE
10.2.5.3 SELEGILINE
10.2.5.4 TRANYLCYPROMINE
10.2.5.5 OTHERS
10.2.6 PROTON PUMP INHIBITORS
10.2.6.1 ESOMEPRAZOLE
10.2.6.2 LANSOPRAZOLE
10.2.6.3 OMEPRAZOLE
10.2.6.4 RABEPRAZOLE
10.2.6.5 PANTOPRAZOLE
10.2.6.6 OTHERS
10.2.7 ALTERNATE THERAPY
10.2.7.1 VITAMIN E
10.2.7.2 GINKO
10.2.7.3 OTHERS
10.2.7.4 OTHERS
10.3 THERAPY
10.3.1 COGNITIVE STIMULATION THERAPY
10.3.2 COGNITIVE BEHAVIORAL THERAPY (CBT)
11 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
11.1 OVERVIEW
11.2 ORAL
11.2.1 TABLET
11.2.2 SYRUP
11.2.3 OTHERS
11.3 PARENTERAL
11.3.1 INTRAVENOUS
11.3.2 INTRAMUSCULAR
11.3.3 OTHERS
11.4 OTHERS
12 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DRUG TYPE
12.1 OVERVIEW
12.2 GENERICS
12.3 BRANDED
13 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY GENDER
13.1 OVERVIEW
13.2 MALE
13.3 FEMALE
14 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY AGE
14.1 OVERVIEW
14.2 GERIATRIC
14.3 ADULT
14.4 CHILD
15 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY END USER
15.1 OVERVIEW
15.2 HOSPITALS
15.3 SPECIALTY CLINICS
15.4 HOMECARE
15.5 OTHERS
16 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 HOSPITAL PHARMACY
16.3 RETAIL PHARMACY
16.3.1 RETAIL SHOPS
16.3.2 ONLINE PHARMACY
17 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION
17.1 ASIA-PACIFIC
17.1.1 CHINA
17.1.2 JAPAN
17.1.3 INDIA
17.1.4 SOUTH KOREA
17.1.5 AUSTRALIA
17.1.6 SINGAPORE
17.1.7 THAILAND
17.1.8 INDONESIA
17.1.9 PHILIPPINES
17.1.10 MALAYSIA
17.1.11 VIETNAM
17.1.12 REST OF ASIA-PACIFIC
18 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC
19 SWOT ANALYSIS
20 COMPANY PROFILE
20.1 EISAI CO., LTD
20.1.1 COMPANY SNAPSHOT
20.1.2 REVENUE ANALYSIS
20.1.3 COMPANY SHARE ANALYSIS
20.1.4 PRODUCT PORTFOLIO
20.1.5 RECENT DEVELOPMENTS
20.1.5.1 PRODUCT LAUNCH
20.2 TEVA PHARMACEUTICAL INDUSTRIES LTD
20.2.1 COMPANY SNAPSHOT
20.2.2 REVENUE ANALYSIS
20.2.3 COMPANY SHARE ANALYSIS
20.2.4 PRODUCT PORTFOLIO
20.2.5 RECENT DEVELOPMENT
20.3 NOVARTIS AG
20.3.1 COMPANY SNAPSHOT
20.3.2 REVENUE ANALYSIS
20.3.3 COMPANY SHARE ANALYSIS
20.3.4 PRODUCT PORTFOLIO
20.3.5 RECENT DEVELOPMENT
20.4 VIATRIS, INC
20.4.1 COMPANY SNAPSHOT
20.4.2 REVENUE ANALYSIS
20.4.3 COMPANY SHARE ANALYSIS
20.4.4 PRODUCT PORTFOLIO
20.4.5 RECENT DEVELOPMENT
20.5 SUN PHARMACEUTICALS INDUSTRIES LTD
20.5.1 COMPANY SNAPSHOT
20.5.2 REVENUE ANALYSIS
20.5.3 COMPANY SHARE ANALYSIS
20.5.4 PRODUCT PORTFOLIO
20.5.5 RECENT DEVELOPMENT
20.6 PFIZER INC.
20.6.1 COMPANY SNAPSHOT
20.6.2 REVENUE ANALYSIS
20.6.3 PRODUCT PORTFOLIO
20.6.4 RECENT DEVELOPMENT
20.7 ASTRAZENECA
20.7.1 COMPANY SNAPSHOT
20.7.2 REVENUE ANALYSIS
20.7.3 PRODUCT PORTFOLIO
20.7.4 RECENT DEVELOPMENT
20.7.4.1 ACQUISITION
20.8 DR. REDDY’S LABORATORIES LTD.
20.8.1 COMPANY SNAPSHOT
20.8.2 REVENUE ANALYSIS
20.8.3 PRODUCT PORTFOLIO
20.8.4 RECENT DEVELOPMENTS
20.9 AUROBINDO PHARMA
20.9.1 COMPANY SNAPSHOT
20.9.2 REVENUE ANALYSIS
20.9.3 PRODUCT PORFOLIO
20.9.4 RECENT DEVELOPMENT
20.9.4.1 PRODUCT APPROVAL
20.1 F.HOFFMANN-LA ROCHE LTD.
20.10.1 COMPANY SNAPSHOT
20.10.2 REVENUE ANALYSIS
20.10.3 PRODUCT PORTFOLIO
20.10.4 RECENT DEVELOPMENT
20.11 ABBVIE INC.
20.11.1 COMPANY SNAPSHOT
20.11.2 REVENUE ANALYSIS
20.11.3 PRODUCT PORTFOLIO
20.11.4 RECENT DEVELOPMENT
20.11.4.1 DATA PRESENTATION
20.12 ACCORD-UK LTD
20.12.1 COMPANY SNAPSHOT
20.12.2 PRODUCT PORTFOLIO
20.12.3 RECENT DEVELOPMENT
20.13 CIPLA INC.
20.13.1 COMPANY SNAPSHOT
20.13.2 REVENUE ANALYSIS
20.13.3 PRODUCT PORTFOLIO
20.13.4 RECENT DEVELOPMENT
20.14 HIKMA PHARMACEUTICALS PLC
20.14.1 COMPANY SNAPSHOT
20.14.2 REVENUE ANALYSIS
20.14.3 PRODUCT PORTFOLIO
20.14.4 RECENT DEVELOPMENTS
20.15 JOHNSON & JOHNSON SERVICES, INC.
20.15.1 COMPANY SNAPSHOT
20.15.2 REVENUE ANALYSIS
20.15.3 PRODUCT PORTFOLIO
20.15.4 RECENT DEVELOPMENT
20.16 JUBILANT PHARMA LIMITED
20.16.1 COMPANY SNAPSHOT
20.16.2 REVENUE ANALYSIS
20.16.3 PRODUCT PORTFOLIO
20.16.4 RECENT DEVELOPMENT
20.17 LANNETT
20.17.1 COMPANY SNAPSHOT
20.17.2 REVENUE ANALYSIS
20.17.3 PRODUCT PORTFOLIO
20.17.4 RECENT DEVELOPMENT
20.18 LUPIN
20.18.1 COMPANY SNAPSHOT
20.18.2 REVENUE ANALYSIS
20.18.3 PRODUCT PORTFOLIO
20.18.4 RECENT DEVELOPMENT
20.18.4.1 AGREEMENT
20.19 MALLINCKRODT PHARMACEUTICALS
20.19.1 COMPANY SNAPSHOT
20.19.2 REVENUE ANALYSIS
20.19.3 PRODUCT PORTFOLIO
20.19.4 RECENT DEVELOPMENT
20.2 TAKEDA PHARMACEUTICAL COMPANY LIMITED
20.20.1 COMPANY SNAPSHOT
20.20.2 REVENUE ANALYSIS
20.20.3 PRODUCT PORTFOLIO
20.20.4 RECENT DEVELOPMENT
20.21 UCB S.A., BELGIUM
20.21.1 COMPANY SNAPSHOT
20.21.2 REVENUE ANALYSIS
20.21.3 PRODUCT PORTFOLIO
20.21.4 RECENT DEVELOPMENT
20.22 WOCKHARDT
20.22.1 COMPANY SNAPSHOT
20.22.2 REVENUE ANALYSIS
20.22.3 PRODUCT PORTFOLIO
20.22.4 RECENT DEVELOPMENT
21 QUESTIONNAIRE
22 RELATED REPORTS
Tabellenverzeichnis
TABLE 1 COMMON BENZODIAZEPINES AVAILABLE IN THE U.S.-
TABLE 2 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISEASE TYPE, 2020-2029 (USD THOUSAND)
TABLE 3 ASIA PACIFIC AMNESTIC MCI IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 4 ASIA PACIFIC NON-AMNESTIC MCI IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 5 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 6 ASIA PACIFIC MEDICATION IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 7 ASIA PACIFIC MEDICATION IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 8 ASIA PACIFIC CHOLINESTERASE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 9 ASIA PACIFIC BENZODIAZEPINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 10 ASIA PACIFIC GLUTAMATE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 11 ASIA PACIFIC ANTIHISTAMINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 12 ASIA PACIFIC MAO INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 13 ASIA PACIFIC PROTON PUMP INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 14 ASIA PACIFIC ALTERNATE THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 15 ASIA PACIFIC THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 16 ASIA PACIFIC THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 17 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 18 ASIA PACIFIC ORAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 19 ASIA PACIFIC ORAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 20 ASIA PACIFIC PARENTERAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 21 ASIA PACIFIC PARENTERAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 22 ASIA PACIFIC OTHERS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 23 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)
TABLE 24 ASIA PACIFIC GENERICS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 25 ASIA PACIFIC BRANDED IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 26 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY GENDER, 2020-2029 (USD THOUSAND)
TABLE 27 ASIA PACIFIC MALE IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 28 ASIA PACIFIC FEMALE IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 29 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 30 ASIA PACIFIC GERIATRIC IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 31 ASIA PACIFIC ADULT IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 32 ASIA PACIFIC CHILD IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 33 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 34 ASIA PACIFIC HOSPITALS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 35 ASIA PACIFIC SPECIALITY CLINICS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 36 ASIA PACIFIC HOMECARE IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 37 ASIA PACIFIC OTHERS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 38 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 39 ASIA PACIFIC HOSPITAL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 40 ASIA PACIFIC RETAIL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 41 ASIA PACIFIC RETAIL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 42 ASIA-PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY COUNTRY, 2020-2029 (USD THOUSAND)
TABLE 43 ASIA-PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISEASE TYPE, 2020-2029 (USD THOUSAND)
TABLE 44 ASIA-PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 45 ASIA-PACIFIC MEDICATION IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 46 ASIA-PACIFIC CHOLINESTERASE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 47 ASIA-PACIFIC BENZODIAZEPINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 48 ASIA-PACIFIC GLUTAMATE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 49 ASIA-PACIFIC MAO INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 50 ASIA-PACIFIC PROTON PUMP INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 51 ASIA-PACIFIC ANTIHISTAMINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 52 ASIA-PACIFIC ALTERNATE THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 53 ASIA-PACIFIC THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 54 ASIA-PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 55 ASIA-PACIFIC ORAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 56 ASIA-PACIFIC PARENTERAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 57 ASIA-PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)
TABLE 58 ASIA-PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY GENDER, 2020-2029 (USD THOUSAND)
TABLE 59 ASIA-PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 60 ASIA-PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 61 ASIA-PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 62 ASIA-PACIFIC RETAIL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 63 CHINA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISEASE TYPE, 2020-2029 (USD THOUSAND)
TABLE 64 CHINA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 65 CHINA MEDICATION IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 66 CHINA CHOLINESTERASE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 67 CHINA BENZODIAZEPINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 68 CHINA GLUTAMATE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 69 CHINA MAO INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 70 CHINA PROTON PUMP INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 71 CHINA ANTIHISTAMINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 72 CHINA ALTERNATE THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 73 CHINA THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 74 CHINA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 75 CHINA ORAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 76 CHINA PARENTERAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 77 CHINA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)
TABLE 78 CHINA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY GENDER, 2020-2029 (USD THOUSAND)
TABLE 79 CHINA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 80 CHINA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 81 CHINA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 82 CHINA RETAIL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 83 JAPAN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISEASE TYPE, 2020-2029 (USD THOUSAND)
TABLE 84 JAPAN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 85 JAPAN MEDICATION IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 86 JAPAN CHOLINESTERASE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 87 JAPAN BENZODIAZEPINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 88 JAPAN GLUTAMATE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 89 JAPAN MAO INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 90 JAPAN PROTON PUMP INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 91 JAPAN ANTIHISTAMINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 92 JAPAN ALTERNATE THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 93 JAPAN THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 94 JAPAN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 95 JAPAN ORAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 96 JAPAN PARENTERAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 97 JAPAN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)
TABLE 98 JAPAN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY GENDER, 2020-2029 (USD THOUSAND)
TABLE 99 JAPAN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 100 JAPAN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 101 JAPAN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 102 JAPAN RETAIL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 103 INDIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISEASE TYPE, 2020-2029 (USD THOUSAND)
TABLE 104 INDIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 105 INDIA MEDICATION IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 106 INDIA CHOLINESTERASE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 107 INDIA BENZODIAZEPINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 108 INDIA GLUTAMATE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 109 INDIA MAO INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 110 INDIA PROTON PUMP INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 111 INDIA ANTIHISTAMINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 112 INDIA ALTERNATE THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 113 INDIA THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 114 INDIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 115 INDIA ORAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 116 INDIA PARENTERAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 117 INDIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)
TABLE 118 INDIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY GENDER, 2020-2029 (USD THOUSAND)
TABLE 119 INDIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 120 INDIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 121 INDIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 122 INDIA RETAIL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 123 SOUTH KOREA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISEASE TYPE, 2020-2029 (USD THOUSAND)
TABLE 124 SOUTH KOREA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 125 SOUTH KOREA MEDICATION IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 126 SOUTH KOREA CHOLINESTERASE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 127 SOUTH KOREA BENZODIAZEPINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 128 SOUTH KOREA GLUTAMATE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 129 SOUTH KOREA MAO INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 130 SOUTH KOREA PROTON PUMP INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 131 SOUTH KOREA ANTIHISTAMINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 132 SOUTH KOREA ALTERNATE THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 133 SOUTH KOREA THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 134 SOUTH KOREA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 135 SOUTH KOREA ORAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 136 SOUTH KOREA PARENTERAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 137 SOUTH KOREA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)
TABLE 138 SOUTH KOREA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY GENDER, 2020-2029 (USD THOUSAND)
TABLE 139 SOUTH KOREA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 140 SOUTH KOREA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 141 SOUTH KOREA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 142 SOUTH KOREA RETAIL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 143 AUSTRALIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISEASE TYPE, 2020-2029 (USD THOUSAND)
TABLE 144 AUSTRALIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 145 AUSTRALIA MEDICATION IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 146 AUSTRALIA CHOLINESTERASE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 147 AUSTRALIA BENZODIAZEPINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 148 AUSTRALIA GLUTAMATE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 149 AUSTRALIA MAO INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 150 AUSTRALIA PROTON PUMP INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 151 AUSTRALIA ANTIHISTAMINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 152 AUSTRALIA ALTERNATE THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 153 AUSTRALIA THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 154 AUSTRALIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 155 AUSTRALIA ORAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 156 AUSTRALIA PARENTERAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 157 AUSTRALIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)
TABLE 158 AUSTRALIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY GENDER, 2020-2029 (USD THOUSAND)
TABLE 159 AUSTRALIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 160 AUSTRALIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 161 AUSTRALIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 162 AUSTRALIA RETAIL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 163 SINGAPORE MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISEASE TYPE, 2020-2029 (USD THOUSAND)
TABLE 164 SINGAPORE MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 165 SINGAPORE MEDICATION IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 166 SINGAPORE CHOLINESTERASE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 167 SINGAPORE BENZODIAZEPINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 168 SINGAPORE GLUTAMATE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 169 SINGAPORE MAO INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 170 SINGAPORE PROTON PUMP INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 171 SINGAPORE ANTIHISTAMINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 172 SINGAPORE ALTERNATE THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 173 SINGAPORE THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 174 SINGAPORE MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 175 SINGAPORE ORAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 176 SINGAPORE PARENTERAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 177 SINGAPORE MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)
TABLE 178 SINGAPORE MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY GENDER, 2020-2029 (USD THOUSAND)
TABLE 179 SINGAPORE MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 180 SINGAPORE MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 181 SINGAPORE MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 182 SINGAPORE RETAIL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 183 THAILAND MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISEASE TYPE, 2020-2029 (USD THOUSAND)
TABLE 184 THAILAND MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 185 THAILAND MEDICATION IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 186 THAILAND CHOLINESTERASE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 187 THAILAND BENZODIAZEPINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 188 THAILAND GLUTAMATE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 189 THAILAND MAO INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 190 THAILAND PROTON PUMP INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 191 THAILAND ANTIHISTAMINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 192 THAILAND ALTERNATE THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 193 THAILAND THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 194 THAILAND MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 195 THAILAND ORAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 196 THAILAND PARENTERAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 197 THAILAND MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)
TABLE 198 THAILAND MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY GENDER, 2020-2029 (USD THOUSAND)
TABLE 199 THAILAND MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 200 THAILAND MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 201 THAILAND MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 202 THAILAND RETAIL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 203 INDONESIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISEASE TYPE, 2020-2029 (USD THOUSAND)
TABLE 204 INDONESIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 205 INDONESIA MEDICATION IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 206 INDONESIA CHOLINESTERASE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 207 INDONESIA BENZODIAZEPINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 208 INDONESIA GLUTAMATE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 209 INDONESIA MAO INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 210 INDONESIA PROTON PUMP INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 211 INDONESIA ANTIHISTAMINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 212 INDONESIA ALTERNATE THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 213 INDONESIA THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 214 INDONESIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 215 INDONESIA ORAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 216 INDONESIA PARENTERAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 217 INDONESIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)
TABLE 218 INDONESIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY GENDER, 2020-2029 (USD THOUSAND)
TABLE 219 INDONESIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 220 INDONESIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 221 INDONESIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 222 INDONESIA RETAIL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 223 PHILIPPINES MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISEASE TYPE, 2020-2029 (USD THOUSAND)
TABLE 224 PHILIPPINES MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 225 PHILIPPINES MEDICATION IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 226 PHILIPPINES CHOLINESTERASE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 227 PHILIPPINES BENZODIAZEPINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 228 PHILIPPINES GLUTAMATE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 229 PHILIPPINES MAO INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 230 PHILIPPINES PROTON PUMP INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 231 PHILIPPINES ANTIHISTAMINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 232 PHILIPPINES ALTERNATE THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 233 PHILIPPINES THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 234 PHILIPPINES MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 235 PHILIPPINES ORAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 236 PHILIPPINES PARENTERAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 237 PHILIPPINES MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)
TABLE 238 PHILIPPINES MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY GENDER, 2020-2029 (USD THOUSAND)
TABLE 239 PHILIPPINES MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 240 PHILIPPINES MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 241 PHILIPPINES MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 242 PHILIPPINES RETAIL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 243 MALAYSIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISEASE TYPE, 2020-2029 (USD THOUSAND)
TABLE 244 MALAYSIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 245 MALAYSIA MEDICATION IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 246 MALAYSIA CHOLINESTERASE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 247 MALAYSIA BENZODIAZEPINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 248 MALAYSIA GLUTAMATE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 249 MALAYSIA MAO INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 250 MALAYSIA PROTON PUMP INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 251 MALAYSIA ANTIHISTAMINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 252 MALAYSIA ALTERNATE THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 253 MALAYSIA THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 254 MALAYSIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 255 MALAYSIA ORAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 256 MALAYSIA PARENTERAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 257 MALAYSIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)
TABLE 258 MALAYSIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY GENDER, 2020-2029 (USD THOUSAND)
TABLE 259 MALAYSIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 260 MALAYSIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 261 MALAYSIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 262 MALAYSIA RETAIL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 263 VIETNAM MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISEASE TYPE, 2020-2029 (USD THOUSAND)
TABLE 264 VIETNAM MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 265 VIETNAM MEDICATION IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 266 VIETNAM CHOLINESTERASE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 267 VIETNAM BENZODIAZEPINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 268 VIETNAM GLUTAMATE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 269 VIETNAM MAO INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 270 VIETNAM PROTON PUMP INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 271 VIETNAM ANTIHISTAMINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 272 VIETNAM ALTERNATE THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 273 VIETNAM THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 274 VIETNAM MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 275 VIETNAM ORAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 276 VIETNAM PARENTERAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 277 VIETNAM MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)
TABLE 278 VIETNAM MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY GENDER, 2020-2029 (USD THOUSAND)
TABLE 279 VIETNAM MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 280 VIETNAM MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 281 VIETNAM MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 282 VIETNAM RETAIL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 283 REST OF ASIA-PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISEASE TYPE, 2020-2029 (USD THOUSAND)
Abbildungsverzeichnis
FIGURE 1 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: SEGMENTATION
FIGURE 2 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: END USERS COVERAGE GRID
FIGURE 8 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 9 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: SEGMENTATION
FIGURE 11 NORTH AMERICA IS ANTICIPATED TO DOMINATE AND ASIA-PACIFIC IS ESTIMATED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 ONGOING RESEARCH TO INCREASE THE THERAPEUTICS APPLICATION IS EXPECTED TO DRIVE THE ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 13 AMNESTIC MCI SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET IN 2022 & 2029
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET
FIGURE 15 DISEASE BURDEN BY RISK FACTOR, WORLDWIDE, 2019
FIGURE 16 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DISEASE TYPE, 2021
FIGURE 17 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DISEASE TYPE, 2020-2029 (USD THOUSAND)
FIGURE 18 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DISEASE TYPE, CAGR (2022-2029)
FIGURE 19 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DISEASE TYPE, LIFELINE CURVE
FIGURE 20 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY TREATMENT, 2021
FIGURE 21 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY TREATMENT, 2020-2029 (USD THOUSAND)
FIGURE 22 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY TREATMENT, CAGR (2022-2029)
FIGURE 23 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 24 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2021
FIGURE 25 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
FIGURE 26 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)
FIGURE 27 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 28 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DRUG TYPE, 2021
FIGURE 29 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DRUG TYPE, 2020-2029 (USD THOUSAND)
FIGURE 30 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DRUG TYPE, CAGR (2022-2029)
FIGURE 31 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 32 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY GENDER, 2021
FIGURE 33 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY GENDER, 2020-2029 (USD THOUSAND)
FIGURE 34 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY GENDER, CAGR (2022-2029)
FIGURE 35 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY GENDER, LIFELINE CURVE
FIGURE 36 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY AGE, 2021
FIGURE 37 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY AGE, 2020-2029 (USD THOUSAND)
FIGURE 38 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY AGE, CAGR (2022-2029)
FIGURE 39 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY AGE, LIFELINE CURVE
FIGURE 40 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY END USER, 2021
FIGURE 41 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY END USER, 2020-2029 (USD THOUSAND)
FIGURE 42 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY END USER, CAGR (2022-2029)
FIGURE 43 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 44 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 45 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
FIGURE 46 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 47 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 48 ASIA-PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: SNAPSHOT (2021)
FIGURE 49 ASIA-PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY COUNTRY (2021)
FIGURE 50 ASIA-PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY COUNTRY (2022 & 2029)
FIGURE 51 ASIA-PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY COUNTRY (2021 & 2029)
FIGURE 52 ASIA-PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DISEASE TYPE (2022-2029)
FIGURE 53 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: COMPANY SHARE 2021 (%)
Forschungsmethodik
Die Datenerfassung und Basisjahresanalyse werden mithilfe von Datenerfassungsmodulen mit großen Stichprobengrößen durchgeführt. Die Phase umfasst das Erhalten von Marktinformationen oder verwandten Daten aus verschiedenen Quellen und Strategien. Sie umfasst die Prüfung und Planung aller aus der Vergangenheit im Voraus erfassten Daten. Sie umfasst auch die Prüfung von Informationsinkonsistenzen, die in verschiedenen Informationsquellen auftreten. Die Marktdaten werden mithilfe von marktstatistischen und kohärenten Modellen analysiert und geschätzt. Darüber hinaus sind Marktanteilsanalyse und Schlüsseltrendanalyse die wichtigsten Erfolgsfaktoren im Marktbericht. Um mehr zu erfahren, fordern Sie bitte einen Analystenanruf an oder geben Sie Ihre Anfrage ein.
Die wichtigste Forschungsmethodik, die vom DBMR-Forschungsteam verwendet wird, ist die Datentriangulation, die Data Mining, die Analyse der Auswirkungen von Datenvariablen auf den Markt und die primäre (Branchenexperten-)Validierung umfasst. Zu den Datenmodellen gehören ein Lieferantenpositionierungsraster, eine Marktzeitlinienanalyse, ein Marktüberblick und -leitfaden, ein Firmenpositionierungsraster, eine Patentanalyse, eine Preisanalyse, eine Firmenmarktanteilsanalyse, Messstandards, eine globale versus eine regionale und Lieferantenanteilsanalyse. Um mehr über die Forschungsmethodik zu erfahren, senden Sie eine Anfrage an unsere Branchenexperten.
Anpassung möglich
Data Bridge Market Research ist ein führendes Unternehmen in der fortgeschrittenen formativen Forschung. Wir sind stolz darauf, unseren bestehenden und neuen Kunden Daten und Analysen zu bieten, die zu ihren Zielen passen. Der Bericht kann angepasst werden, um Preistrendanalysen von Zielmarken, Marktverständnis für zusätzliche Länder (fordern Sie die Länderliste an), Daten zu klinischen Studienergebnissen, Literaturübersicht, Analysen des Marktes für aufgearbeitete Produkte und Produktbasis einzuschließen. Marktanalysen von Zielkonkurrenten können von technologiebasierten Analysen bis hin zu Marktportfoliostrategien analysiert werden. Wir können so viele Wettbewerber hinzufügen, wie Sie Daten in dem von Ihnen gewünschten Format und Datenstil benötigen. Unser Analystenteam kann Ihnen auch Daten in groben Excel-Rohdateien und Pivot-Tabellen (Fact Book) bereitstellen oder Sie bei der Erstellung von Präsentationen aus den im Bericht verfügbaren Datensätzen unterstützen.
